Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua K M Wong

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Trends in Cancer|November 15, 2022
Weaponizing natural killer cells for solid cancer immunotherapyJoshua K M Wong, Riccardo Dolcetti, Handoo Rhee, et al.
Ebiomedicine|May 29, 2024
TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancerJoshua K M Wong, Timothy R McCulloch, Louisa Alim, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2025
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapyJoshua K M Wong, Pui Yeng Lam, Elaina Coleborn, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Trends in Cancer|November 15, 2022
Weaponizing natural killer cells for solid cancer immunotherapyJoshua K M Wong, Riccardo Dolcetti, Handoo Rhee, et al.
Ebiomedicine|May 29, 2024
TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancerJoshua K M Wong, Timothy R McCulloch, Louisa Alim, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2025
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapyJoshua K M Wong, Pui Yeng Lam, Elaina Coleborn, et al.
Pageof 1